LOGIN  |  REGISTER
Assertio

Lineage Cell Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

November 14, 2024 | Last Trade: US$0.56 0.06 11.16
  • OpRegen® Granted Regenerative Medicine Advanced Therapy (RMAT) Designation From FDA
  • ReSonance™ (ANP1) Preclinical Results Presented at 59th Annual Inner Ear Biology Workshop
  • Added to 2024 Russell 3000® Index

CARLSBAD, Calif. / Nov 14, 2024 / Business Wire / Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported its third quarter 2024 financial and operating results. The Company will host a conference call today at 4:30 p.m. Eastern Time to discuss these results and to provide a business update.

“We were delighted to see our partners’ continued commitment to the OpRegen program, in this instance by seeking and successfully obtaining RMAT designation,” stated Brian M. Culley, Lineage CEO. “We believe OpRegen continues to showcase itself as an asset with the potential to be ‘a transformational medicine’ and view the recent RMAT designation as additional positive progress for this pioneering cell transplant program. As we worked to return our second cell transplant program, OPC1 for spinal cord injury, back into the clinic, we also presented promising preclinical results from our third program, ReSonance, for sensorineural hearing loss. We look forward to continuing to create value through the advancement of our clinical and preclinical pipelines, applying both our technology and extensive manufacturing expertise to validate our cell transplant approach.”

Recent Operational Highlights

- RG6501 (OpRegen)

  • Roche and Genentech, a member of the Roche Group, announced receipt of RMAT designation from the U.S. FDA for OpRegen, for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
  • Continued execution under our collaboration with Roche and Genentech across multiple functional areas, including support for the ongoing Phase 2a clinical study (the “GAlette Study”) in patients with GA secondary to AMD.
  • Continued activities under the separate services agreement with Genentech to support ongoing development of OpRegen. Lineage has been providing additional clinical, technical, training and manufacturing services funded by Genentech, that further support the ongoing advancement and optimization of the OpRegen program and include: (i) activities to support the ongoing Phase 1/2a study and currently-enrolling Phase 2a study; and (ii) additional technical training and materials related to Lineage’s cell therapy technology platform to support commercial manufacturing strategies.

- OPC1

  • DOSED (Delivery of Oligodendrocyte Progenitor Cells for Spinal Cord Injury: Evaluation of a Novel Device) clinical study for the treatment of subacute and chronic spinal cord patient start-up activities and FDA interactions continue.

- ReSonance (ANP1)

  • Preclinical results presented at 59th Annual Inner Ear Biology Workshop
    • ReSonance manufactured by a proprietary process, developed in-house, at clinical scale, with relevant in-vitro functional activity
    • Immediate-use, thaw-and-inject formulation durably engrafted in multiple preclinical hearing loss models
    • ReSonance is currently being evaluated in a functional model of hearing loss through a collaboration with the University of Michigan Kresge Hearing Research Institute.

Balance Sheet Highlights

Cash, cash equivalents, and marketable securities of $32.7 million as of September 30, 2024 is expected to support planned operations into Q1 2026.

Third Quarter Operating Results

Revenues: Revenue is generated primarily from collaboration revenues, royalties, and other revenues. Total revenues for the three months ended September 30, 2024 were $3.8 million, a net increase of approximately $2.5 million as compared to approximately $1.2 million for the same period in 2023. The increase was primarily driven by more collaboration revenue recognized from deferred revenues under the collaboration and license agreement with Roche.

Operating Expenses: Operating expenses are comprised of research and development (R&D) expenses and general and administrative (G&A) expenses. Total operating expenses for the three months ended September 30, 2024 were $7.6 million, a decrease of $0.3 million as compared to $7.9 million for the same period in 2023.

R&D Expenses: R&D expenses for the three months ended September 30, 2024 were $3.2 million, a net decrease of approximately $0.6 million as compared to $3.7 million for the same period in 2023. The net decrease was primarily driven by $0.6 million for our OPC1 program, $0.4 million for our preclinical programs, and partially offset by $0.5 million for our OpRegen program.

G&A Expenses: G&A expenses for the three months ended September 30, 2024 were $4.4 million, a net increase of $0.4 million as compared to $4.0 million for the same period in 2023. The net increase was primarily driven by $0.3 million for personnel costs and $0.1 million for stock-based compensation expense.

Loss from Operations: Loss from operations for the three months ended September 30, 2024 were $3.8 million, a decrease of $2.9 million as compared to $6.7 million for the same period in 2023.

Other Income/(Expenses): Other income (expenses) for the three months ended September 30, 2024 reflected other income of $0.8 million, compared to other expenses of approximately ($0.4) million for the same period in 2023. The change was primarily driven by exchange rate fluctuations related to our international subsidiaries.

Net Loss Attributable to Lineage: The net loss attributable to Lineage for the three months ended September 30, 2024 was $3.0 million, or $0.02 per share (basic and diluted), compared to a net loss attributable to Lineage of $7.1 million, or $0.04 per share (basic and diluted), for the same period in 2023.

Conference Call and Webcast

Interested parties may access the conference call on November 14th, 2024, by dialing (800) 715-9871 from the U.S. and Canada and should request the “Lineage Cell Therapeutics Call”. A live webcast of the conference call will be available online in the Investors section of Lineage’s website. A replay of the webcast will be available on Lineage’s website for 30 days and a telephone replay will be available through November 21st, 2024, by dialing (800) 770-2030 from the U.S. and Canada and entering conference ID number 2238934.

About Lineage Cell Therapeutics, Inc.

Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel, “off-the-shelf,” cell therapies to address unmet medical needs. Lineage’s programs are based on its proprietary cell-based technology platform and associated development and manufacturing capabilities. From this platform, Lineage designs, develops, manufactures, and tests specialized human cells with anatomical and physiological functions similar or identical to cells found naturally in the human body. These cells are created by applying directed differentiation protocols to established, well-characterized, and self-renewing pluripotent cell lines. These protocols generate cells with characteristics associated with specific and desired developmental lineages. Cells derived from such lineages are transplanted into patients in an effort to replace or support cells that are absent or dysfunctional due to degenerative disease, aging, or traumatic injury, and to restore or augment the patient’s functional activity. Lineage’s neuroscience focused pipeline currently includes: (i) OpRegen, a retinal pigment epithelial cell therapy in Phase 2a development under a worldwide collaboration with Roche and Genentech, a member of the Roche Group, for the treatment of geographic atrophy secondary to age-related macular degeneration; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase 1/2a development for the treatment of spinal cord injuries; (iii) ReSonance (ANP1), an auditory neuronal progenitor cell therapy for the potential treatment of auditory neuropathy; (iv) PNC1, a photoreceptor neural cell therapy for the potential treatment of vision loss due to photoreceptor dysfunction or damage; and (v) RND1, a novel hypoimmune induced pluripotent stem cell line being developed in collaboration with Factor Bioscience Limited. For more information, please visit www.lineagecell.com or follow the company on X/Twitter @LineageCell.

Forward-Looking Statements

Lineage cautions you that all statements, other than statements of historical facts, contained in this press release, are forward-looking statements. Forward-looking statements, in some cases, can be identified by terms such as “believe,” “aim,” “may,” “will,” “estimate,” “continue,” “anticipate,” “design,” “intend,” “expect,” “could,” “can,” “plan,” “potential,” “predict,” “seek,” “should,” “would,” “contemplate,” “project,” “target,” “tend to,” or the negative version of these words and similar expressions. Lineage’s forward-looking statements are based upon its current expectations and beliefs and involve assumptions that may never materialize or may prove to be incorrect. Such statements include, but are not limited to, statements relating to: the potential therapeutic benefits of OpRegen in patients with GA secondary to AMD and the potential impacts of RMAT designation on Roche and Genentech’s development of OpRegen or OpRegen’s ultimate success; the benefits of our new services agreement with Genentech and its impact on advancing the OpRegen program; the commencement of the DOSED clinical study for OPC1; that our cash, cash equivalents and marketable securities is sufficient to support our planned operations into the first quarter of 2026; the impacts to Lineage of our continued inclusion within the Russell 3000 Index; the broad potential for Lineage’s regenerative medicine platform and our ability to develop additional product candidates; and the potential of our platform technology and/or manufacturing capabilities to validate our approach or create value. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Lineage’s actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by the forward-looking statements in this press release, including, but not limited to, the following risks: that we may need to allocate our cash to unexpected events and expenses causing us to use our cash, cash equivalents and marketable securities more quickly than expected; that development activities, preclinical activities, and clinical trials of our product candidates may not commence, progress or be completed as expected due to many factors within and outside of our control; that positive findings in early clinical and/or nonclinical studies of a product candidate may not be predictive of success in subsequent clinical and/or nonclinical studies of that candidate; that OpRegen may never be proven to provide durable anatomical functional improvements in dry-AMD patients or become a ‘transformational medicine’, that competing alternative therapies may adversely impact the commercial potential of OpRegen; that Roche and Genentech may not successfully advance OpRegen or be successful in completing further clinical trials for OpRegen and/or obtaining regulatory approval for OpRegen in any particular jurisdiction; that OPC1 may not advance further in any clinical trials, and if it does, that any such clinical trials may not be successful; that the ongoing Israel-Hamas war and broader regional conflict may materially and adversely impact our manufacturing processes, including cell banking and product manufacturing for our cell therapy product candidates, all of which are conducted by our subsidiary in Jerusalem, Israel; that Lineage may not be able to manufacture sufficient clinical quantities of its product candidates in accordance with current good manufacturing practice; and those risks and uncertainties inherent in Lineage’s business and other risks discussed in Lineage’s filings with the Securities and Exchange Commission (SEC). Further information regarding these and other risks is included under the heading “Risk Factors” in Lineage’s periodic reports with the SEC, including Lineage’s most recent Annual Report on Form 10-K filed with the SEC and its other subsequent reports, which are available from the SEC’s website. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Lineage undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law. All forward-looking statements are expressly qualified in their entirety by these cautionary statements.

     

LINEAGE CELL THERAPEUTICS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(IN THOUSANDS)

(UNAUDITED)

     

 

 

September 30, 2024

 

December 31, 2023

ASSETS

 

 

 

 

CURRENT ASSETS

 

 

 

 

Cash and cash equivalents

 

$

27,750

 

 

$

35,442

 

Marketable securities

 

 

4,961

 

 

 

50

 

Accounts receivable, net

 

 

405

 

 

 

745

 

Prepaid expenses and other current assets

 

 

1,285

 

 

 

2,204

 

Total current assets

 

 

34,401

 

 

 

38,441

 

 

 

 

 

 

NONCURRENT ASSETS

 

 

 

 

Property and equipment, net

 

 

2,013

 

 

 

2,245

 

Operating lease right-of-use assets

 

 

2,362

 

 

 

2,522

 

Deposits and other long-term assets

 

 

606

 

 

 

577

 

Goodwill

 

 

10,672

 

 

 

10,672

 

Intangible assets, net

 

 

46,540

 

 

 

46,562

 

TOTAL ASSETS

 

$

96,594

 

 

$

101,019

 

 

 

 

 

 

LIABILITIES AND SHAREHOLDERS’ EQUITY

 

 

 

 

CURRENT LIABILITIES

 

 

 

 

Accounts payable and accrued liabilities

 

$

4,477

 

 

$

6,270

 

Operating lease liabilities, current portion

 

 

1,083

 

 

 

830

 

Finance lease liabilities, current portion

 

 

54

 

 

 

52

 

Deferred revenues, current portion

 

 

8,250

 

 

 

10,808

 

Total current liabilities

 

 

13,864

 

 

 

17,960

 

 

 

 

 

 

LONG-TERM LIABILITIES

 

 

 

 

Deferred tax liability

 

 

273

 

 

 

273

 

Deferred revenues, net of current portion

 

 

16,050

 

 

 

18,693

 

Operating lease liabilities, net of current portion

 

 

1,533

 

 

 

1,979

 

Finance lease liabilities, net of current portion

 

 

80

 

 

 

91

 

TOTAL LIABILITIES

 

 

31,800

 

 

 

38,996

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

SHAREHOLDERS’ EQUITY

 

 

 

 

Preferred shares, no par value, 2,000 shares authorized; none issued and outstanding as of September 30, 2024 and December 31, 2023

 

 

 

 

 

 

Common shares, no par value, 450,000 shares authorized as of September 30, 2024 and December 31, 2023; 188,837 and 174,987 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively

 

 

469,268

 

 

 

451,343

 

Accumulated other comprehensive loss

 

 

(2,890

)

 

 

(3,068

)

Accumulated deficit

 

 

(400,192

)

 

 

(384,856

)

Lineage's shareholders’ equity

 

 

66,186

 

 

 

63,419

 

Noncontrolling deficit

 

 

(1,392

)

 

 

(1,396

)

Total shareholders’ equity

 

 

64,794

 

 

 

62,023

 

TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY

 

$

96,594

 

 

$

101,019

 

         
     

LINEAGE CELL THERAPEUTICS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(IN THOUSANDS, EXCEPT PER SHARE DATA)

(UNAUDITED)

     

 

 

Three Months Ended

September 30,

 

Nine Months Ended

September 30,

 

 

 

2024

 

 

 

2023

 

 

 

2024

 

 

 

2023

 

REVENUES:

 

 

 

 

 

 

 

 

Collaboration revenues

 

$

3,386

 

 

$

957

 

 

$

5,671

 

 

$

5,949

 

Royalties, license and other revenues

 

 

393

 

 

 

289

 

 

 

960

 

 

 

908

 

Total revenues

 

 

3,779

 

 

 

1,246

 

 

 

6,631

 

 

 

6,857

 

 

 

 

 

 

 

 

 

 

OPERATING EXPENSES:

 

 

 

 

 

 

 

 

Cost of sales

 

 

38

 

 

 

169

 

 

 

180

 

 

 

415

 

Research and development

 

 

3,171

 

 

 

3,741

 

 

 

9,049

 

 

 

11,799

 

General and administrative

 

 

4,410

 

 

 

4,041

 

 

 

13,770

 

 

 

13,014

 

Total operating expenses

 

 

7,619

 

 

 

7,951

 

 

 

22,999

 

 

 

25,228

 

Loss from operations

 

 

(3,840

)

 

 

(6,705

)

 

 

(16,368

)

 

 

(18,371

)

 

 

 

 

 

 

 

 

 

OTHER INCOME (EXPENSES):

 

 

 

 

 

 

 

 

Interest income

 

 

397

 

 

 

433

 

 

 

1,322

 

 

 

1,225

 

Loss on marketable equity securities, net

 

 

(6

)

 

 

(60

)

 

 

(21

)

 

 

(170

)

Foreign currency transaction gain (loss), net

 

 

448

 

 

 

(827

)

 

 

(284

)

 

 

(1,796

)

Other income (expense)

 

 

 

 

 

1

 

 

 

19

 

 

 

544

 

Total other income (expenses)

 

 

839

 

 

 

(453

)

 

 

1,036

 

 

 

(197

)

 

 

 

 

 

 

 

 

 

LOSS BEFORE INCOME TAXES

 

 

(3,001

)

 

 

(7,158

)

 

 

(15,332

)

 

 

(18,568

)

 

 

 

 

 

 

 

 

 

Provision for income tax benefit

 

 

 

 

 

 

 

 

 

 

 

1,803

 

 

 

 

 

 

 

 

 

 

NET LOSS

 

 

(3,001

)

 

 

(7,158

)

 

 

(15,332

)

 

 

(16,765

)

 

 

 

 

 

 

 

 

 

Net (income) loss attributable to noncontrolling interest

 

 

(33

)

 

 

48

 

 

 

(4

)

 

 

54

 

 

 

 

 

 

 

 

 

 

NET LOSS ATTRIBUTABLE TO LINEAGE

 

$

(3,034

)

 

$

(7,110

)

 

$

(15,336

)

 

$

(16,711

)

 

 

 

 

 

 

 

 

 

Net loss per common share attributable to Lineage basic and diluted

 

$

(0.02

)

 

$

(0.04

)

 

$

(0.08

)

 

$

(0.10

)

 

 

 

 

 

 

 

 

 

Weighted-average common shares used to compute basic and diluted net loss per common share

 

 

188,835

 

 

 

174,868

 

 

 

186,860

 

 

 

171,880

 

                 
   

LINEAGE CELL THERAPEUTICS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(IN THOUSANDS)

(UNAUDITED)

   

 

 

Nine Months Ended September 30,

 

 

 

2024

 

 

 

2023

 

CASH FLOWS FROM OPERATING ACTIVITIES:

 

 

 

 

Net loss attributable to Lineage

 

$

(15,336

)

 

$

(16,711

)

Net loss attributable to noncontrolling interest

 

 

4

 

 

 

(54

)

Adjustments to reconcile net loss attributable to Lineage Cell Therapeutics, Inc. to net cash used in operating activities:

 

 

 

 

Loss on marketable equity securities, net

 

 

21

 

 

 

170

 

Accretion of income on marketable debt securities

 

 

(184

)

 

 

(647

)

Depreciation and amortization expense

 

 

436

 

 

 

419

 

Change in right-of-use assets and liabilities

 

 

(31

)

 

 

86

 

Amortization of intangible assets

 

 

22

 

 

 

98

 

Stock-based compensation

 

 

3,762

 

 

 

3,580

 

Deferred income tax benefit

 

 

 

 

 

(1,803

)

Foreign currency remeasurement and other loss

 

 

309

 

 

 

1,892

 

Changes in operating assets and liabilities:

 

 

 

 

Accounts receivable

 

 

339

 

 

 

(141

)

Prepaid expenses and other current assets

 

 

891

 

 

 

56

 

Accounts payable and accrued liabilities

 

 

(1,778

)

 

 

(3,456

)

Deferred revenue

 

 

(5,201

)

 

 

(6,036

)

Net cash used in operating activities

 

 

(16,746

)

 

 

(22,547

)

 

 

 

 

 

CASH FLOWS FROM INVESTING ACTIVITIES:

 

 

 

 

Proceeds from the sale of marketable equity securities

 

 

18

 

 

 

196

 

Purchases of marketable debt securities

 

 

(8,761

)

 

 

(16,403

)

Maturities of marketable debt securities

 

 

4,000

 

 

 

53,497

 

Purchase of equipment

 

 

(200

)

 

 

(583

)

Net cash (used in) provided by investing activities

 

 

(4,943

)

 

 

36,707

 

 

 

 

 

 

CASH FLOWS FROM FINANCING ACTIVITIES:

 

 

 

 

Proceeds from employee options exercised

 

 

229

 

 

 

88

 

Common shares received and retired for employee taxes paid

 

 

(23

)

 

 

(37

)

Proceeds from sale of common shares

 

 

14,070

 

 

 

6,625

 

Payments for offering costs

 

 

(113

)

 

 

(199

)

Repayment of finance lease liabilities

 

 

(40

)

 

 

(41

)

Net cash provided by financing activities

 

 

14,123

 

 

 

6,436

 

Effect of exchange rate changes on cash, cash equivalents and restricted cash

 

 

(120

)

 

 

(532

)

NET (DECREASE) INCREASE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH

 

 

(7,686

)

 

 

20,064

 

 

 

 

 

 

CASH, CASH EQUIVALENTS AND RESTRICTED CASH:

 

 

 

 

At beginning of the period

 

 

35,992

 

 

 

11,936

 

At end of the period

 

$

28,306

 

 

$

32,000

 

 

 

 

 

 

SUPPLEMENTAL DISCLOSURES:

 

 

 

 

Cash paid for interest

 

$

6

 

 

$

8

 

 

 

 

 

 

SUPPLEMENTAL SCHEDULE OF NON-CASH FINANCING AND
INVESTING ACTIVITIES:

 

 

 

 

Property and equipment expenditures in accounts payable

 

$

11

 

 

$

8

 

 

 

 

 

 

Reconciliation of cash, cash equivalents and restricted cash, end of period:

 

 

 

 

Cash and cash equivalents

 

$

27,750

 

 

$

31,474

 

Restricted cash included in deposits and other long-term assets (see Note 13 (Commitments and Contingencies))

 

 

556

 

 

 

526

 

Total cash, cash equivalents, and restricted cash

 

$

28,306

 

 

$

32,000

 

 

Recursion

Stock Quote

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

Featured Stock

Recursion

Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB